| abstract |
The present invention relates to Lck inhibitors already known as kinase inhibitors for treatment in oncology in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunosuppressants, biomodifiers and anti-infectives. Use of a method for treating a pathological condition associated with an immune disease or immune component, a pharmaceutical composition comprising the Lck inhibitor together with the other agent, and a pathological condition associated with an immune disease or immune component of the Lck inhibitor It relates to the use for the manufacture of a therapeutic pharmaceutical composition. |